Skip to main content
Erschienen in: Pediatric Rheumatology 1/2022

Open Access 01.12.2022 | Case Report

Kawasaki disease complicated by peripheral artery thrombosis: a case report and literature review

verfasst von: Nanjun Zhang, Li Yu, Zhongxian Xiong, Yimin Hua, Hongyu Duan, Lina Qiao, Kaiyu Zhou, Chuan Wang

Erschienen in: Pediatric Rheumatology | Ausgabe 1/2022

Abstract

Background

Peripheral gangrene is rarely documented as a possible complication of Kawasaki disease (KD). There are many causes of peripheral gangrene, and the common cause is in situ thrombosis or embolism. Most cases are reported to have regrettable outcomes (amputation or necrotic shedding). Herein, we report the successful management of KD complicated by peripheral artery thrombosis in an older Chinese boy, and a review of all cases of peripheral gangrene in KD in the literature.

Case presentation

We found that most of the children with this complication were under 1 year old, had a heavy inflammatory response combined with the use of cortisol and immunoglobulin, and most children had coronary artery lesions. In addition, Peripheral gangrene mainly occurred in the subacute or chronic stage, and the prognosis is poor.

Conclusions

In the presence of high risk factors, we consider it is necessary to monitor coagulation function and administer prophylactic anticoagulation therapy. When peripheral artery thrombosis or embolism occur, heparin and prostaglandins can be used for treatment.
Hinweise
Nanjun Zhang, Li Yu and Zhongxian Xiong contributed equally to this work.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
KD
Kawasaki disease
IVIG
Intravenous immunoglobulin
ECG
Electrocardiogram
DIC
Disseminated intravascular coagulation

Background

Kawasaki disease (KD) is an acute systemic vasculitis of unknown origin that predominantly affects children aged 6 months to 5 years. In addition to the classic clinical features, KD can also affect multiple organs and tissues. The involvement of the pulmonary, gastrointestinal, neurological, and urinary systems has been well recognized and reported in patients with KD. In addition, aneurysms with or without extracardiac muscular arteries, including the brachial, common iliac, internal iliac, abdominal aortic, subclavian, and femoral arteries, have been recently uncovered in KD patients [1, 2].
However, peripheral gangrene has rarely been documented as a possible complication of KD. To the best of our knowledge, 25 cases have been reported in the literature. Almost all of these patients were younger than 1 year, and most were associated with coronary artery aneurysms. No similar cases have been described in the Chinese population. Most importantly, because most cases are reported with regrettable outcomes (amputation or necrotic shedding), it is of great importance and clinical significance to gain a better understanding of this rare complication in KD. Early identification and timely treatment of KD complicated by peripheral gangrene can greatly improve the prognosis and reverse the occurrence of adverse outcomes; however, little is known about this disorder in KD.
Herein, the successful management of peripheral artery thrombosis complicated by KD in an older Chinese boy was reported, and all cases of peripheral gangrene in KD in the literature were reviewed, aiming to improve the awareness and recognition of pediatricians and to share experiences regarding the management strategies for this rare complication in KD.

Case presentation

A boy aged 4 years and 9 months was admitted to a local hospital with persistent fever for 1 day (June 4, 2021). Two days before the onset of fever, a painful lump appeared on the right side of his neck. On the second day of the disease, the child had fever with a temperature of 39 °C, and enlarged lymph nodes 2 cm × 2 cm in size, palpable in the right neck. The results of blood cell examination of the local hospital indicated a significant increase in leukocytes (leukocytes 19.25 × 10^9/L, normal range 4.03–11.09 × 10^9/L; 88% neutrophils; 6.5% lymphocytes), a decrease in hemoglobin (108 g/L, normal range 108–144 g/L), normal platelet count (385 × 10^9/L, normal range 128–420 × 10^9/L), and elevated C-reactive protein (CRP 87 mg/L, normal range 0–8 mg/L). The erythrocyte sedimentation rate was accelerated (ESR 71 mm/h, normal range, < 25 mm/h). Ultrasonography of the neck revealed enlargement of lymph nodes on both sides. The local hospital thought that the fever was caused by cervical lymphadenitis and gave the child amoxicillin-clavulanate potassium treatment (dosage and time of use were unknown). However, the child still had a persistent high fever, and new symptoms appeared on the fifth day of the disease. The patient developed a full-body congestive rash, bilateral bulbar conjunctival injection without exudate, flushed and chapped lips, swollen extremities, mild abdominal pain, and vomiting. These are the typical symptoms of KD. Because the patient had refractory fever for more than 5 days, the anti-infection treatment effect was poor, and five of the current clinical symptoms met the criteria of Kawasaki disease. Combined with white blood cells, CRP was elevated, and he was quickly diagnosed with Kawasaki disease. The local hospital quickly perfected other tests. Laboratory findings showed a significant elevation of liver enzymes (ALT 229 U/L, normal range < 49 U/L; AST 145 U/L, normal range < 40 U/L), myocardial injury with elevated brain natriuretic peptide (BNP) of 3050 pg/mL (normal range 0–100 pg/mL) and cardiac troponin T (cTnT) of 13.74 pg/mL (normal range 0–0.06μg/L). Simultaneously, color ultrasound of the abdomen showed enlargement of the liver, CT of the abdomen showed enlargement of the gallbladder, and echocardiography showed no coronary dilation. The local hospital adjusted the treatment regimen and administered aspirin (50 mg/kg, orally), IVIG (2 g/kg, intravenous drip), and antiemetic and liver-protecting medicines (specific drugs are not available). However, the treatment not effective. The vomiting and abdominal pain subsided, but the child still had a persistent high fever (after 48 h of immunoglobulin administration), and blood culture was negative. Therefore, the patient was administered a second dose of immunoglobulin (2 g/kg, intravenous drip).
On the 9th day of the illness (48 h after the second dose of immunoglobulin), the child was transferred to our hospital due to persistent high fever. Physical examination after admission showed persistent high fever, bilateral cervical lymph node enlargement, bilateral bulbar conjunctival injection without exudate, stiff and swollen extremities, warm limbs, normal arterial pulsation, and capillary filling time < 2 s. Laboratory blood tests indicated an increase in leukocytes (21.7 × 10^9/L, 92.9% neutrophils, 5.2% lymphocytes), decreased hemoglobin (81 g/L), increased CRP (194.3 mg/L), increased ESR(71 mm/h), and elevated BNP (1136.25 pg/mL). Liver function and myocardial injury index returned to normal. The electrocardiogram (ECG) was normal, and echocardiography suggested normal coronary artery (LCA = 2.9 mm, Z-score = 1.81; LAD = 2.1 mm, Z-score = 0.76; LCX = 1.9 mm, Z-score = 0.75; RCA = 2.4 mm, Z-score = 1.34). The possibility of multisystem inflammatory syndrome in children (MIS-C) [3, 4] was also excluded since two novel coronavirus nucleic acid tests outside the hospital and in our hospital were negative.
The boy was immediately administered intravenous methylprednisolone (20 mg/kg/day for 5 days) and a third dose of immunoglobulin (2 g/kg). On the 14th day of illness, the child’s temperature returned to normal. We reexamined the child’s echocardiography, which indicated left ventricular enlargement (LV = 38 mm; no dilation of left and right coronary arteries, LCA = 2.8 mm, Z-score = 1.55; LAD = 2.1 mm, Z-score = 0.76; LCX = 1.9 mm, Z-score = 0.75; RCA = 2.4 mm, Z-score = 1.34). The patient seemed to be doing well, so we gradually cut back on methylprednisolone. Unfortunately, on day 19 of the disease, the boy developed pain in his right index finger, cyanosis and desquamation of the end of the index finger, decreased temperature, and decreased palpation of the arterial pulse. Laboratory examination of disseminated intravascular coagulation (DIC) indicated blood hypercoagulability: decreased fibrinogen, increased fibrinogen degradation product, and D-dimer (Fg 50 mg/dL, normal range, 200–400 mg/dL; FDPs 38.10 μg/mL, normal range < 5μg/mL; DDI 12.02 mg/L FEU; normal range < 0.55 mg/L). Apparently, the patient had an arterial thrombosis in his right finger. Because the blood glucose of the fingertips was measured on the left hand, we ruled out thrombosis caused by an external puncture injury. At the same time, we performed a right upper limb artery ultrasound examination and echocardiography, and no obvious embolism or thrombosis was found. By reviewing the relevant literature, we found that 25 patients with KD presented with complications of peripheral gangrene [524], Therefore we believe that this peripheral thrombosis was related to KD.
Within 4 h of peripheral arterial thrombosis discovery in the child, we successively administered urokinase (100,000 U urokinase was given three times intravenously, 30 min apart), low molecular weight heparin calcium (100 U/kg, intravenously for 5 days) and alprostadil (0.5 ng/kg/min intravenously for 5 days) for anticoagulant thrombolytic therapy. In the course of treatment, we continuously evaluated the blood supply to the right finger, avoided fingertip blood glucose measurement, and monitored coagulation function. Fortunately, perfusion of the index finger extremity was gradually restored on the 23rd day of the disease, the skin color of the extremity was ruddy, the temperature returned to normal, and the coagulation function gradually returned to normal (Fig. 1).
On the 25th day of the disease, the patient was discharged after oral aspirin administration (5 mg/kg per day). After discharge, his regular follow-up echocardiography and ECG findings were normal, and the function of his right finger was restored without sequelae. His condition was improving positively.

Discussion

Peripheral arterial thrombosis is rare in patients with KD. We report the first case of refractory KD complicated by a peripheral artery thrombosis in a Chinese population. By reviewing the literature on 25 cases of KD complicated by peripheral gangrene, we discuss possible reasons, prevention, and treatment strategies. Based on our experience and previous information, we hope to improve peers’ understanding of KD complications and provide insights on prevention and treatment.
We compiled the clinical data of 25 children with Kawasaki disease complicated by peripheral gangrene, and we found some noteworthy phenomena: among the 25 patients (Table 1), the age distribution was mainly concentrated in infants under 1 year old (21 cases, 84%, range 1 month to 1 years, including 11 boys and 10 girls), and four children were older than 1 year (7 years, 4 years, 3.5 years, and 14 months). The mean time to onset of KD complicated by peripheral gangrene was 16.1 days (range 5th to 41stdays, 2 data were unavailable). This is different from what we thought, which occurs mainly in the subacute phase. Additionally, in terms of complications, most patients had coronary artery lesions (5 cases of dilatation and 18 cases of coronary aneurysm) and dilatation of other arteries in some cases. In terms of treatment methods, immunoglobulin use was 21/24 cases (of which multiple immunoglobulin use was 9/21 cases, some data were unavailable), most children showed IVIG resistance (16/21 cases, data were unavailable in some cases), cortisol use was 15/24 cases (some data were unavailable), and immunoglobulin combined with cortisol hormone use was 15/24 cases (some data were unavailable). In addition, the current treatment for Kawasaki disease complicated by peripheral gangrene is mainly anticoagulation, thrombolysis, and vasodilator use; of these patients, 11/21 (some data not available) remained gangrenous after treatment (eight amputations, three partial amputations, or detachments) and 13/21 recovered or improved after treatment (nine with no sequelae, three with partial recovery, and one with sequelae). Of these, 19/21 used anticoagulants (including heparin and warfarin; 10/19 improved or recovered after treatment; 9/19 amputation, partial amputation, or detachment), 6/21 used vasodilators (including nitroglycerin and prostaglandins; 5/6 improved or recovered after treatment; 1/6 amputation, partial amputation, or detachment), and 3/21 thrombolytic therapy (including t-PA and urokinase; 1/3 improvement or recovery after treatment; 2/3 amputation, partial amputation, or detachment). Anticoagulation and thrombolytic therapy were used together in 2/21 cases (1/2 improvement or recovery after treatment; 1/2 amputation, partial amputation, or detachment), and anticoagulation and vasodilators were used together in 9/21 cases (4/9 improvement or recovery after treatment; 5/9 amputation, partial amputation, or detachment).
Table 1
Baseline data of 25 children
References
Sex/Age (month)
Incomplete KD
Coronary artery lesions
IVIG
Corticosteroids treatment
Immunosuppressive and biological agentsb
Peripheral gangrene site
Abnormal timing of peripheral gangrene
Recovery time from peripheral gangrene
Prognosis of peripheral gangrene
Anticoagulation, thrombolytic and other therapy (Besides aspirin)a
Fatemeh Tahghighi et al.
F/8
Dilatation
(+)/2 doses
(+)
NA
Knee
26th
56th
No significant sequelae
Iran Malekzadeh et al.
M/4
Incomplete
Multiple aneurysms
(+)
(+)
2
On both sides lower and right fingers
NA
Amputation
1
F/6
Incomplete
Dilatation
(+)
(+)
NA
Right fingers
NA
NA
No significant sequelae
NA
M/12
Incomplete
Multiple aneurysms
(+)/2 doses
(+)
1,4
Fingers
20th
NA
No significant sequelae
1,2
M. von Planta et al.
F/2
incomplete
Multiple aneurysms
(+)
NA
NA
Left fingers, right toes
18th
40th
No significant sequelae
1,3
Na Yeon Kim et al.
M/57d
Multiple aneurysms
(+)/4 doses
(+)
3
Left fingers, right toes
14th
22nd
No significant sequelae
1,2
Jai Prakash Son et al.
M/4Y
incomplete
Normal
(+)
NA
NA
Left side of the lower lip and left finger
7th
NA
No significant sequelae
1
Matthew J.O’Connor et al.
M/7 weeks
incomplete
Multiple aneurysms
(+)/2 doses
(+)
NA
Left toes and the left finger
8th
NA
NA
1,4
A. L. Durall et al.
M/1
Multiple aneurysms
(+)/2 doses
(+)
NA
Hands and feet
14th
Amputation
1,4,8
Faten Al Tasseh et al.
M/ 14
incomplete
Dilatation
(+)
(+)
NA
right fingers
9th
Amputation
1,3,5
Shobun Tomita et al.
F/ 2
incomplete
Multiple aneurysms and Coronary artery thrombosis
(+)/2 doses
NA
NA
Left fingers
22th
23rd, Partial improvement
Partial amputation
1,2,3,4,6,7
M/2
incomplete
Multiple aneurysms
(+)
NA
NA
The left hand
17th
22nd, Partial improvement
Partial amputation
1,2
F/3
Multiple aneurysms
(+)/3 doses
(+)
NA
left hand (at the wrist), left leg (at the knee), and
18th
Amputation
1
right foot (at the ankle)
C. Krohn et al.
F/3
Incomplete
Aneurysms
(+)
(+)
NA
The left hand and left foot
28th
Amputation
1,6
Mark A. Westphalen et al.
M/5
Aneurysms
(+)
(+)
NA
Hands
18th
28th, Most improvement
Partly leaving after-effects
3,4
Elisabeth Gomez Moyano et al.
M/4
Multiple aneurysms
(+)
(+)
NA
Fingers and toes
15th
Amputation
1,3,4
Elliot L. Ames et al.
M/4
Multiple aneurysms
NA
NA
NA
Hands
27th
Amputation
1
O H Teixeira et al.
F/7
Multiple aneurysms
NA
NA
NA
Fingers and toes
16th
70th, Most improvement
NA
NA
Omer Faruk Dogan et al.
F/7Y
Multiple aneurysms
(+)
(+)
NA
Left toes
6th
21st
No significant sequelae
1,3
Muhammad Mohsin et al.
F/10
Dilatation
(+)
NA
NA
Left big toe
7th
10th, Most improvement
No significant sequelae
1,4
J.-S. Chang et al.
M/8.5
Dilatation and Aneurysms
(+)
NA
NA
Fingers and toes
7th
23th, Most improvement
Partial amputation
1
J L Brenner et al.
F/3
Incomplete
Dilatation and Aneurysms
NA
NA
NA
Right toes
41th
Amputation
NA
M/5
Multiple aneurysms
(+)/3 doses
(+)
NA
Big toe
28th
NA
NA
1,2,4,6
Garrido-García LM, et al.
F/45d
NA
NA
NA
NA
NA
Right toes
NA
NA
NA
NA
Madan D et al.
M/3.5Y
Incomplete
Dilatation
(+)/2 doses
(+)
4
Both hands and feet and face
5th
NA
No significant sequelae
1
a1. Heparin, 2. Warfarin, 3. Prostaglandin, 4. Nitroglycerin, 5. Fresh frozen plasma, 6. tissue type PA(t-PA), 7. Urokinase, 8. antithrombin III
b1. Azathioprine; 2. Cyclophosphamide; 3. Methotrexate; 4. Infliximab
A number of mechanisms have been proposed for the potential mechanisms of peripheral gangrene complicating Kawasaki disease, although they are not fully understood. First, the inflammatory response is associated with a hypercoagulable state of the blood. The immune inflammatory response in children with Kawasaki disease can lead to the destruction of vascular endothelial cells, followed by a decrease in platelets and activation of the coagulation system. This leads to the formation of blood clots. Most children with KD suffering from peripheral gangrene have a strong immune inflammatory response, as evidenced by the development of vascular complications, young age (< 1 year of age), immunoglobulin resistance phenomena, the need for cortisol hormones or immunosuppressants, and the presence of coronary aneurysms or other peripheral arterial damage. However, this is not absolute, and we also found that children with Kawasaki disease at older ages and without coronary artery dilation may also have peripheral gangrene complications (as in the case we reported and in a previous child with Kawasaki disease at age 7 years without coronary artery dilation), which also reminds us that older children with Kawasaki disease without coronary artery dilation, deserve to be examined. In addition, several previous studies have reported the presence of a hypercoagulable blood state in patients with KD in the acute phase, with D-dimer being associated with CRP [2532]. The significant elevation of CRP in our patient also suggests a high risk factor. However, this is also somewhat controversial, as we found that the mean time to the onset of KD complicated by peripheral gangrene was 16.1 days (range 5th–41st days, 2 data were unavailable). Contrary to our hypothesis, it occurred mainly in the subacute phase. This may be a continuation of the rapid inflammatory response in the acute phase, but it may also be a delay in the therapeutic window owing to the difficulty of early recognition and the paucity of information available for preventive decision-making. Second, treatment with some medications seems to contribute to the development of this complication to some extent. The most common treatment for children with Kawasaki disease with intense inflammation is the use of immunoglobulins and hormones, but thrombotic complications are well-known complications of immunoglobulin therapy and may be related to increased blood viscosity, the procoagulant activity of the immunoglobulins, and the immunoglobulin-induced arterial vasospasm [33]. The use of cortisol hormones is also known to increase the viscosity of blood and promote thrombosis. The almost unavoidable use of immunoglobulins and hormones, even multiple times, in previous case reports and in our case, reminds us, on the other hand, that treatment should be accompanied by great vigilance for the development of arterial thrombosis. Third, spasms of the peripheral arteries may also play a role. The stimulation of blood vessels by drugs, spasm of peripheral arteries due to inflammation, and puncture of peripheral arteries during treatment (such as fingertip blood glucose monitoring and arterial blood gas analysis) may lead to peripheral artery spasm, thus causing a change in hemodynamics and the occurrence of peripheral artery thrombosis. Fourth, the research of Huang MY et al. [34] showed that the capillary morphology was abnormal when compared to controls in KD, with a larger diameter of the arterial and venous limbs, a higher intercapillary distance and a decrease in the loop numbers. Significantly decreased capillary blood cell velocity was noted in afebrile phase. The deceleration of the flow velocity of the extremities may become a high risk factor for thrombosis in KD and contribute to the peripheral artery thrombosis in our case. .
Treatment of KD complicated by peripheral gangrene or peripheral artery thrombosis is rare and not mentioned in current guidelines, and most cases are empirically treated from the perspective of arterial thrombosis, which makes us very passive in treatment plan decisions. The main treatment is anticoagulation, thrombolysis, and use of vasodilators; of these patients, 11/21 (some data were unavailable) were known to remain gangrenous after treatment (eight amputations, three partial amputations or detachments) and 13/21 recovered or improved after treatment (nine with no sequelae, three with partial recovery, and one with sequelae). Of these, 19/21 used anticoagulants (including heparin and warfarin, 10/19 improved or recovered after treatment; 9/19 amputation, partial amputation, or detachment), 6/21 used vasodilators (including nitroglycerin and prostaglandins; 5/6 improved or recovered after treatment; 1/6 amputation, partial amputation, or detachment), and 3/21 thrombolytic therapy (including t-PA and urokinase; 1/3 improvement or recovery after treatment; 2/3 amputation, partial amputation, or detachment). Anticoagulation and thrombolytic therapy were used together in 2/21 cases (1/2 improvement or recovery after treatment; 1/2 amputation, partial amputation, or detachment), and anticoagulation and vasodilators were used together in 9/21 cases (4/9 improvement or recovery after treatment; 5/9 amputation, partial amputation, or detachment). In addition, it is widely proved that hyperbaric oxygen therapy could ameliorate diseases with impaired oxygen supply due to capillary injury or vascular obstruction. For the reported 25 cases with peripheral artery thrombosis in KD, none of them received hyperbaric oxygen therapy and half of them remained gangrenous after treatment. Therefore, hyperbaric oxygen therapy may serve as an adjunct therapeutic option for peripheral artery thrombosis in KD if these children were unresponsive for the treatment of anticoagulation, thrombolysis, and use of vasodilators.
In summary, when a child has a high-risk factor for age less than 1 year, intense inflammatory response, multiple IVIG and cortisol hormone use, and the presence of coronary artery damage, a high degree of vigilance is needed for the development of peripheral artery thrombosis or peripheral gangrene, especially during the subacute phase of KD. However, we report a case of Kawasaki disease complicated by peripheral artery thrombosis in an older child without coronary artery damage in China, which on the other hand reminds us that an older child without coronary artery damage needs equal attention. When this KD complication occurs, early treatment with thrombolysis combined with anticoagulation seems to reduce the occurrence of adverse outcomes, and prostaglandin analogs can be used as a therapeutic option.

Conclusions

KD complicated by peripheral artery thrombosis is very rare, and it can lead to peripheral gangrene. The early prevention, recognition, and treatment can reduce the probability of amputation. We report the first case of an older Chinese child with KD complicated by peripheral artery thrombosis. Through this case report and literature review, we found that most children with this complication were under 1 year old, had a heavy inflammatory response combined with the use of cortisol and immunoglobulin, and most children had coronary artery lesions. In addition, peripheral gangrene mainly occurs in the subacute or chronic stage, and the prognosis is poor. Therefore, in the presence of these high-risk factors, it is necessary to monitor coagulation function and administer prophylactic anticoagulation therapy. Heparin and prostaglandins can be used for treatment of peripheral artery thrombosis.

Acknowledgements

We are grateful to the patients and families for their contributions to this work.

Declarations

Not applicable.
Written informed consent was obtained from the individual(s), and minor(s)’ legal guardian/next of kin, for the publication of any potentially identifiable images or data included in this article.

Competing interests

All authors have no conflict of interests or any grants to declare.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
2.
Zurück zum Zitat Fukazawa R, Kobayashi J, Ayusawa M, et al. JCS/JSCS 2020 guideline on diagnosis and management of cardiovascular sequelae in Kawasaki disease. Circ J. 2020;84(8):1348–407.CrossRef Fukazawa R, Kobayashi J, Ayusawa M, et al. JCS/JSCS 2020 guideline on diagnosis and management of cardiovascular sequelae in Kawasaki disease. Circ J. 2020;84(8):1348–407.CrossRef
3.
Zurück zum Zitat Jiang L, Tang K, Levin M, et al. COVID-19 and multisystem inflammatory syndrome in children and adolescents. Lancet Infect Dis. 2020;20(11):e276–e88.CrossRef Jiang L, Tang K, Levin M, et al. COVID-19 and multisystem inflammatory syndrome in children and adolescents. Lancet Infect Dis. 2020;20(11):e276–e88.CrossRef
4.
Zurück zum Zitat Sharma C, Ganigara M, Galeotti C, et al. Multisystem inflammatory syndrome in children and Kawasaki disease: a critical comparison. Nat Rev Rheumatol. 2021;17(12):731–48.CrossRef Sharma C, Ganigara M, Galeotti C, et al. Multisystem inflammatory syndrome in children and Kawasaki disease: a critical comparison. Nat Rev Rheumatol. 2021;17(12):731–48.CrossRef
5.
Zurück zum Zitat Tahghighi F, Bakhtiari Koohsorkhi M, Ziaee V. Peripheral gangerene, an unusual presentation of infantile Kawasaki: a case report and literature review. Case Rep Rheumatol. 2021;2021:6629405.PubMedPubMedCentral Tahghighi F, Bakhtiari Koohsorkhi M, Ziaee V. Peripheral gangerene, an unusual presentation of infantile Kawasaki: a case report and literature review. Case Rep Rheumatol. 2021;2021:6629405.PubMedPubMedCentral
6.
Zurück zum Zitat Malekzadeh I, Ziaee V, Sadrosadat T, Moardinejad M-H, Sayadpour-Zanjani K. Kawasaki disease and peripheral gangrene in infancy. Iran J Pediatr. 2015;25(6):e3309.CrossRef Malekzadeh I, Ziaee V, Sadrosadat T, Moardinejad M-H, Sayadpour-Zanjani K. Kawasaki disease and peripheral gangrene in infancy. Iran J Pediatr. 2015;25(6):e3309.CrossRef
7.
Zurück zum Zitat Kim NY, Choi DY, Jung MJ, Jeon I-S. A case of refractory Kawasaki disease complicated by peripheral ischemia. Pediatr Cardiol. 2008;29(6):1110–4.CrossRef Kim NY, Choi DY, Jung MJ, Jeon I-S. A case of refractory Kawasaki disease complicated by peripheral ischemia. Pediatr Cardiol. 2008;29(6):1110–4.CrossRef
8.
Zurück zum Zitat Bonté I, Mahr A, Laroche L, Guillevin L, Robineau M. Peripheral gangrene in adult-onset Kawasaki disease. Scand J Rheumatol. 2005;34(1):71–3.CrossRef Bonté I, Mahr A, Laroche L, Guillevin L, Robineau M. Peripheral gangrene in adult-onset Kawasaki disease. Scand J Rheumatol. 2005;34(1):71–3.CrossRef
9.
Zurück zum Zitat Soni JP, Makwana M, Jetha K, Mantri A. Atypical Kawasaki disease- dilatation of ascending aorta and peripheral gangrene. J Evid Based Med Healthc. 2017;4(23):1358–61.CrossRef Soni JP, Makwana M, Jetha K, Mantri A. Atypical Kawasaki disease- dilatation of ascending aorta and peripheral gangrene. J Evid Based Med Healthc. 2017;4(23):1358–61.CrossRef
10.
Zurück zum Zitat O'Connor MJ, Saulsbury FT. Incomplete and atypical Kawasaki disease in a young infant: severe, recalcitrant disease responsive to infliximab. Clin Pediatr (Phila). 2007;46(4):345–8.CrossRef O'Connor MJ, Saulsbury FT. Incomplete and atypical Kawasaki disease in a young infant: severe, recalcitrant disease responsive to infliximab. Clin Pediatr (Phila). 2007;46(4):345–8.CrossRef
11.
Zurück zum Zitat Durall AL, Phillips JR, Weisse ME, Mullett CJ. Infantile Kawasaki disease and peripheral gangrene. J Pediatr. 2006;149(1):131–3.CrossRef Durall AL, Phillips JR, Weisse ME, Mullett CJ. Infantile Kawasaki disease and peripheral gangrene. J Pediatr. 2006;149(1):131–3.CrossRef
12.
Zurück zum Zitat Al Tasseh F, El Khatib H, Kordab R, et al. Kawasaki disease complicated by peripheral gangrene in a case of inherited thrombophilia. Int J Clin Pediatr. 2018;7(3):43–5.CrossRef Al Tasseh F, El Khatib H, Kordab R, et al. Kawasaki disease complicated by peripheral gangrene in a case of inherited thrombophilia. Int J Clin Pediatr. 2018;7(3):43–5.CrossRef
13.
Zurück zum Zitat Tomita S, Chung K, Mas M, Gidding S, Shulman ST. Peripheral gangrene associated with Kawasaki disease. Clin Infect Dis. 1992;14(1):121–6.CrossRef Tomita S, Chung K, Mas M, Gidding S, Shulman ST. Peripheral gangrene associated with Kawasaki disease. Clin Infect Dis. 1992;14(1):121–6.CrossRef
14.
Zurück zum Zitat Krohn C, Till H, Haraida S, et al. Multiple intestinal stenoses and peripheral gangrene: a combination of two rare surgical complications in a child with Kawasaki disease. J Pediatr Surg. 2001;36(4):651–3.CrossRef Krohn C, Till H, Haraida S, et al. Multiple intestinal stenoses and peripheral gangrene: a combination of two rare surgical complications in a child with Kawasaki disease. J Pediatr Surg. 2001;36(4):651–3.CrossRef
15.
Zurück zum Zitat Westphalen MA, McGrath MA, Kelly W, Moore FJ, Ziegler JB. Kawasaki disease with severe peripheral ischemia: treatment with prostaglandin E1 infusion. J Pediatr. 1988;112(3):431–3.CrossRef Westphalen MA, McGrath MA, Kelly W, Moore FJ, Ziegler JB. Kawasaki disease with severe peripheral ischemia: treatment with prostaglandin E1 infusion. J Pediatr. 1988;112(3):431–3.CrossRef
16.
Zurück zum Zitat Gomez-Moyano E, Vera Casaño A, Camacho J, Sanz Trelles A, Crespo-Erchiga V. Kawasaki disease complicated by cutaneous vasculitis and peripheral gangrene. J Am Acad Dermatol. 2011;64(5):e74–e5.CrossRef Gomez-Moyano E, Vera Casaño A, Camacho J, Sanz Trelles A, Crespo-Erchiga V. Kawasaki disease complicated by cutaneous vasculitis and peripheral gangrene. J Am Acad Dermatol. 2011;64(5):e74–e5.CrossRef
17.
Zurück zum Zitat Ames EL, Jones JS, Van Dommelen B, Posch JL. Bilateral hand necrosis in Kawasaki syndrome. J Hand Surg Am. 1985;10(3):391–5.CrossRef Ames EL, Jones JS, Van Dommelen B, Posch JL. Bilateral hand necrosis in Kawasaki syndrome. J Hand Surg Am. 1985;10(3):391–5.CrossRef
18.
19.
Zurück zum Zitat Dogan OF, Kara A, Devrim I, et al. Peripheral gangrene associated with Kawasaki disease and successful management using prostacycline analogue: a case report. Heart Surg Forum. 2007;10(1):E70–E2.CrossRef Dogan OF, Kara A, Devrim I, et al. Peripheral gangrene associated with Kawasaki disease and successful management using prostacycline analogue: a case report. Heart Surg Forum. 2007;10(1):E70–E2.CrossRef
20.
Zurück zum Zitat Mohsin M, Akhtar S. Kawasaki disease complicated by peripheral gangrene and a ventricular septal defect: an unusual association. Turk J Pediatr. 2019;61(2):301–4.CrossRef Mohsin M, Akhtar S. Kawasaki disease complicated by peripheral gangrene and a ventricular septal defect: an unusual association. Turk J Pediatr. 2019;61(2):301–4.CrossRef
21.
Zurück zum Zitat Chang JS, Lin JS, Peng CT, Tsai CH. Kawasaki disease complicated by peripheral gangrene. Pediatr Cardiol. 1999;20(2):139–42.CrossRef Chang JS, Lin JS, Peng CT, Tsai CH. Kawasaki disease complicated by peripheral gangrene. Pediatr Cardiol. 1999;20(2):139–42.CrossRef
22.
Zurück zum Zitat Brenner JL, Jadavji T, Pinto A, Trevenen C, Patton D. Severe Kawasaki disease in infants: two fatal cases. Can J Cardiol. 2000;16(8):1017–23.PubMed Brenner JL, Jadavji T, Pinto A, Trevenen C, Patton D. Severe Kawasaki disease in infants: two fatal cases. Can J Cardiol. 2000;16(8):1017–23.PubMed
24.
Zurück zum Zitat Garrido-Garcia LM, Gutierrez-Alanis JH, Ramirez-Perea AI, Tremoulet A, Yamazaki-Nakashimada MA. Kawasaki disease in infants in the first 3 months of age in a Mexican population: a cautionary tale. Front Pediatr. 2020;8:397.CrossRef Garrido-Garcia LM, Gutierrez-Alanis JH, Ramirez-Perea AI, Tremoulet A, Yamazaki-Nakashimada MA. Kawasaki disease in infants in the first 3 months of age in a Mexican population: a cautionary tale. Front Pediatr. 2020;8:397.CrossRef
25.
Zurück zum Zitat Shao S, Yang L, Liu X, et al. Predictive value of coagulation profiles for both initial and repeated immunoglobulin resistance in Kawasaki disease: a prospective cohort study. Pediatr Allergy Immunol. 2021;32(6):1349–59.CrossRef Shao S, Yang L, Liu X, et al. Predictive value of coagulation profiles for both initial and repeated immunoglobulin resistance in Kawasaki disease: a prospective cohort study. Pediatr Allergy Immunol. 2021;32(6):1349–59.CrossRef
26.
Zurück zum Zitat Sakurai Y. Autoimmune aspects of Kawasaki disease. J Investig Allergol Clin Immunol. 2019;29(4):251–61.CrossRef Sakurai Y. Autoimmune aspects of Kawasaki disease. J Investig Allergol Clin Immunol. 2019;29(4):251–61.CrossRef
27.
Zurück zum Zitat Okada S, Hasegawa S, Suzuki Y, et al. Acute pericardial effusion representing the TNF-α-mediated severe inflammation but not the coronary artery outcome of Kawasaki disease. Scand J Rheumatol. 2015;44(3):247–52.CrossRef Okada S, Hasegawa S, Suzuki Y, et al. Acute pericardial effusion representing the TNF-α-mediated severe inflammation but not the coronary artery outcome of Kawasaki disease. Scand J Rheumatol. 2015;44(3):247–52.CrossRef
28.
Zurück zum Zitat Li Y, Zheng Q, Zou L, et al. Kawasaki disease shock syndrome: clinical characteristics and possible use of IL-6, IL-10 and IFN-γ as biomarkers for early recognition. Pediatr Rheumatol Online J. 2019;17(1):1.CrossRef Li Y, Zheng Q, Zou L, et al. Kawasaki disease shock syndrome: clinical characteristics and possible use of IL-6, IL-10 and IFN-γ as biomarkers for early recognition. Pediatr Rheumatol Online J. 2019;17(1):1.CrossRef
29.
Zurück zum Zitat Hu P, Jiang GM, Wu Y, et al. TNF-α is superior to conventional inflammatory mediators in forecasting IVIG nonresponse and coronary arteritis in Chinese children with Kawasaki disease. Clin Chim Acta. 2017;471:76–80.CrossRef Hu P, Jiang GM, Wu Y, et al. TNF-α is superior to conventional inflammatory mediators in forecasting IVIG nonresponse and coronary arteritis in Chinese children with Kawasaki disease. Clin Chim Acta. 2017;471:76–80.CrossRef
30.
Zurück zum Zitat Foley JH, Conway EM. Cross talk pathways between coagulation and inflammation. Circ Res. 2016;118(9):1392–408.CrossRef Foley JH, Conway EM. Cross talk pathways between coagulation and inflammation. Circ Res. 2016;118(9):1392–408.CrossRef
31.
Zurück zum Zitat Selleri C, Sato T, Anderson S, Young NS, Maciejewski JP. Interferon-gamma and tumor necrosis factor-alpha suppress both early and late stages of hematopoiesis and induce programmed cell death. J Cell Physiol. 1995;165(3):538–46.CrossRef Selleri C, Sato T, Anderson S, Young NS, Maciejewski JP. Interferon-gamma and tumor necrosis factor-alpha suppress both early and late stages of hematopoiesis and induce programmed cell death. J Cell Physiol. 1995;165(3):538–46.CrossRef
32.
Zurück zum Zitat Chelazzi C, Villa G, Mancinelli P, De Gaudio AR, Adembri C. Glycocalyx and sepsis-induced alterations in vascular permeability. Crit Care. 2015;19:26.CrossRef Chelazzi C, Villa G, Mancinelli P, De Gaudio AR, Adembri C. Glycocalyx and sepsis-induced alterations in vascular permeability. Crit Care. 2015;19:26.CrossRef
33.
Zurück zum Zitat Marie I, Maurey G, Hervé F, Hellot MF, Levesque H. Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature. Br J Dermatol. 2006;155(4):714–21.CrossRef Marie I, Maurey G, Hervé F, Hellot MF, Levesque H. Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature. Br J Dermatol. 2006;155(4):714–21.CrossRef
34.
Zurück zum Zitat Huang MY, Huang JJ, Huang TY, Gupta-Malhotra M, Syu FK. Deterioration of cutaneous microcirculatory status of Kawasaki disease. Clin Rheumatol. 2012;31(5):847–52.CrossRef Huang MY, Huang JJ, Huang TY, Gupta-Malhotra M, Syu FK. Deterioration of cutaneous microcirculatory status of Kawasaki disease. Clin Rheumatol. 2012;31(5):847–52.CrossRef
Metadaten
Titel
Kawasaki disease complicated by peripheral artery thrombosis: a case report and literature review
verfasst von
Nanjun Zhang
Li Yu
Zhongxian Xiong
Yimin Hua
Hongyu Duan
Lina Qiao
Kaiyu Zhou
Chuan Wang
Publikationsdatum
01.12.2022
Verlag
BioMed Central
Erschienen in
Pediatric Rheumatology / Ausgabe 1/2022
Elektronische ISSN: 1546-0096
DOI
https://doi.org/10.1186/s12969-022-00738-y

Weitere Artikel der Ausgabe 1/2022

Pediatric Rheumatology 1/2022 Zur Ausgabe

Mit dem Seitenschneider gegen das Reißverschluss-Malheur

03.06.2024 Urologische Notfallmedizin Nachrichten

Wer ihn je erlebt hat, wird ihn nicht vergessen: den Schmerz, den die beim Öffnen oder Schließen des Reißverschlusses am Hosenschlitz eingeklemmte Haut am Penis oder Skrotum verursacht. Eine neue Methode für rasche Abhilfe hat ein US-Team getestet.

Reanimation bei Kindern – besser vor Ort oder während Transport?

29.05.2024 Reanimation im Kindesalter Nachrichten

Zwar scheint es laut einer Studie aus den USA und Kanada bei der Reanimation von Kindern außerhalb einer Klinik keinen Unterschied für das Überleben zu machen, ob die Wiederbelebungsmaßnahmen während des Transports in die Klinik stattfinden oder vor Ort ausgeführt werden. Jedoch gibt es dabei einige Einschränkungen und eine wichtige Ausnahme.

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

28.05.2024 Kinder- und Jugendgynäkologie Nachrichten

Welchen Einfluss das Alter ihrer Mutter auf das Risiko hat, dass Kinder mit nicht chromosomal bedingter Malformation zur Welt kommen, hat eine ungarische Studie untersucht. Sie zeigt: Nicht nur fortgeschrittenes Alter ist riskant.

Begünstigt Bettruhe der Mutter doch das fetale Wachstum?

Ob ungeborene Kinder, die kleiner als die meisten Gleichaltrigen sind, schneller wachsen, wenn die Mutter sich mehr ausruht, wird diskutiert. Die Ergebnisse einer US-Studie sprechen dafür.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.